Navigation Links
UAB study shows investigational drug may treat biliary cancers
Date:4/15/2008

BIRMINGHAM, Ala. -- Laboratory studies by University of Alabama at Birmingham (UAB) researchers have shown that the investigational drug triphendiol (NV-196) causes cell death in pancreatic and bile duct cancer cell lines, slows tumor growth and sensitizes tumors to chemotherapy treatments.

The findings were presented April 13 by Ewan Tytler, Ph.D., assistant professor in the UAB Department of Surgery, Gastrointestinal Section, at the annual meeting of the American Association for Cancer Research (AACR).

Tytler and his colleagues assessed the potential of triphendiol as a treatment for pancreatic adenocarcinoma using three representative cell lines. Triphendiol induced cell death in all three cell lines and pre-treating the cell lines with triphendiol increased the effectiveness of chemotherapy. Animal model studies showed that triphendiol in combination with chemotherapy inhibited tumor growth more effectively than each drug alone.

In our laboratory studies, triphendiol is more potent at inducing cell death in pancreatic and bile duct cancer cells compared to the chemotherapy drug gemcitabine alone at up to 10-fold lower concentrations, Tytler said. Of course, there is still much work to be done before this could become a treatment protocol for cancer patients but our findings are promising and validate the continued development of triphendiol as a possible pancreatic cancer therapy.

Triphendiol is being developed by Marshall Edwards Inc., as a treatment for late stage pancreatic and gall bladder cancer and recently received orphan drug status by the U.S. Food and Drug Administration. Triphendiol has been licensed by Novogen to Marshall Edwards Inc., who funded Tytlers study.

Tytler said that there is an urgent need for new pancreatic cancer treatments because fewer than 20 percent of patients are candidates for surgery. Current treatment is limited to chemotherapy, which is not always effective, as most tumors are res
'/>"/>

Contact: Jennifer Lollar
jpark@uab.edu
205-934-3888
University of Alabama at Birmingham
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Study shows that high-dose, high-frequency interferon produces no additional benefit
2. Study finds media coverage of breast cancer focuses too little on prevention
3. USC study finds evidence of gender-related differences in development of colon cancer
4. New study in JCSM finds that obesity can predict upper airway obstruction amongst children
5. Study shows increase of hip and knee replacements in the US
6. Study shows decline in work disability due to rheumatoid arthritis
7. Study details cost-effectiveness of rheumatoid arthritis treatments for Medicare recipients
8. Study sheds light on deadly lung disease
9. NovoCure presents results from breast cancer pilot study
10. Mayo-led study finds smoking related to subset of colorectal cancers
11. National hospice study reveals gaps in service
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 2014 With the development of ... of adjusting human body physiology, preventing diseases, promoting ... with a variety of specific populations. In 2013, ... reached RMB187.4 billion, up 12.0% year on year, ... View Full Report at http://www.marketresearchreports.biz/analysis/223449 , ...
(Date:9/18/2014)... MA (PRWEB) September 18, 2014 ... its team and surgeon partners in Less Exposure ... joining SpineFrontier, Tamara authored an extensive education curriculum ... a Masters in Science in Organizational Leadership, and ... industries for eleven years. Bringing her to the ...
(Date:9/18/2014)... Dr. Suzaunna Clark, Psychologist, Life Coach ... beauty has to be seen to be believed and ... order to be used. Together, both lead to hearts ... how to do both. , Dr. Clark ... Healing Hearts system, which provides professional guidance on dealing ...
(Date:9/18/2014)... Specialty Teleradiology LLC, a provider of teleradiology services ... achieved Meaningful Use and increased operational efficiency since ... developed by RamSoft. , Before implementing PowerServer ... PACS and a RIS that was built in-house. ... oncology to other subspecialties, they needed a robust, ...
(Date:9/18/2014)... 2014 N-Zyme Scientifics LLC achieved a ... first product a mere 8 months after company startup. ... performance glycan release enzyme used in the “Biologics” industry ... basis for tissue pathology on Mass Spec devices. PRIME™ ... the North American market (PNGase F PRIMETM). N-Zyme ...
Breaking Medicine News(10 mins):Health News:China Health Food Industry Size 2014 Market Analysis, Growth, Trends and Forecast Report 2017: MarketResearchReports.biz 2Health News:China Health Food Industry Size 2014 Market Analysis, Growth, Trends and Forecast Report 2017: MarketResearchReports.biz 3Health News:China Health Food Industry Size 2014 Market Analysis, Growth, Trends and Forecast Report 2017: MarketResearchReports.biz 4Health News:SpineFrontier Inc. Makes Bold Move to Expand Its Internal Training Team to Collaborate With The LESSociety’s Less Exposure Surgery® University To Educate Surgeons. 2Health News:Suzaunna-Where Life! Happens Announces the Launch of Healing Hearts 2Health News:Suzaunna-Where Life! Happens Announces the Launch of Healing Hearts 3Health News:Specialty Teleradiology Attains Meaningful Use with PowerServer MU 2Health News:Specialty Teleradiology Attains Meaningful Use with PowerServer MU 3Health News:N-Zyme Scientifics Announces Successful Product Launch 2
... latest research unhealthy ways of expressing anger are associated ... //expressing anger." According to past research, stress can also ... not practice healthy anger or stress management may be ... adolescents, ages 14 to 17, for three years. In ...
... New research shows one virus could help fight another. ... // hepatitis G , may hold a key ... ,Researchers analyzed results from the Multicenter Acquired ... large group of HIV-infected men in the United States ...
... put a woman at increased risk of developing asthma, report ... obstructive pulmonary disease (COPD) risk. ,The incidence of both ... 5 percent to 8 percent of Americans have asthma, and ... since 1982. Since the prevalence of asthma tends to change ...
... lose significant bone mass in the first year after the ... their bodies from rejecting the new organ. The bone loss ... of fractures among this group ranges from 22 percent to ... treatment, but which drugs work best in this situation is ...
... is showing promising results.For the past decade, researchers // ... immunotoxin is bioengineered and consists of only the most ... commonly used to fight leukemia. One of those immunotoxins, ... study. ,Researchers say in a phase I study, ...
... estimates that 40 million people are infected with the ... In some African countries, 40 percent of pregnant women ... caught HIV. ,In impoverished areas where the ... one-time treatment for HIV-infected pregnant women to keep them ...
Cached Medicine News:Health News:Drug to stop HIV spread to babies may Indirectly harm The Mother 2
(Date:9/18/2014)... and CHESTERBROOK, Pa. , Sept. 18, ... VVUS ) and Auxilium Pharmaceuticals, Inc. (Nasdaq: ... Drug Administration (FDA) has approved a supplemental new drug application ... only FDA-approved erectile dysfunction (ED) medication indicated to be taken ... STENDRA is a prescription medication in a class of ...
(Date:9/17/2014)... , Sept. 17, 2014 BRIC Gynecological ... GlobalData,s new report, "BRIC Gynecological ... data on the BRIC Gynecological Devices market. The ... volume (in units) and average prices (in US ... (Transcervical Sterilization Devices (Micro-inserts) and Mechanical Sterilization Devices ...
(Date:9/17/2014)... MONICA, Calif. , Sept. 17, 2014  Dr. ... is at the White House today for National Recovery ... 46 that consumer advocates released today. Consumer advocates were ... woman who spoke out after losing her fiancée ... discovering that the doctor had a history of crack ...
Breaking Medicine Technology:VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 2VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 3VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 4VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 5VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 6VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 7VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 8VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 9BRIC Gynecological Devices Market Outlook to 2020 2BRIC Gynecological Devices Market Outlook to 2020 3Doctor Recovering From 100-Pill-A-Day Addiction Stars In New Ad Supporting Prop 46; Appears At White House for National Recovery Month, Says Consumer Watchdog Campaign 2Doctor Recovering From 100-Pill-A-Day Addiction Stars In New Ad Supporting Prop 46; Appears At White House for National Recovery Month, Says Consumer Watchdog Campaign 3
... 18, 2011 Adeona Pharmaceuticals, Inc. (Amex: ... central nervous system diseases, announced today that it will ... 8, 2011 from 3:00-5:00 P.M. (EST) at the Kensington ... Arbor, Adeona,s management team welcomes shareholders, potential investors and ...
... Companion Animal Health has launched its second product in ... + milbemycin oxime), a broad-spectrum parasiticide that kills fleas ... flea infestations, the prevention of heartworm disease and the ... infections in dogs and puppies 8 weeks and older, ...
Cached Medicine Technology:Adeona to Host Investor Day on Zinc Deficiency in Alzheimer's Disease 2Adeona to Host Investor Day on Zinc Deficiency in Alzheimer's Disease 3Elanco Launches Broad-Spectrum Canine Parasiticide 2Elanco Launches Broad-Spectrum Canine Parasiticide 3Elanco Launches Broad-Spectrum Canine Parasiticide 4
Hydrophobic PE filter without self-sealing additives, permits sample recovery after accidental over-pipetting. All filters are sterile (to USP, DAB, Ph.Eur. standards) and PCR clean (free from human ...
Ideal for use with low volume samples on the Biomek robotic pipetting systems, the ART 20R provides guaranteed protection for your expensive workstation....
... eliminate false signals and contamination caused ... Promega Barrier Tips offer performance and ... acids (PCR(a)), radioactive isotopes, tissue culture ... specimens. , ,Promega Barrier Tips are ...
... 0.5l - 10l Eppendorf Barrier Tips. Designed to ... reduces the amount of DNA and proteins bound ... advertised as low retention, which means the focus ... tip. However, AvantGard also focuses on low binding ...
Medicine Products: